Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors

(2018) John Nemunaitis et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours

(2017) Maja de Jonge et al.   EUROPEAN JOURNAL OF CANCER

Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors

(2017) Andrew J. Wagner et al.   JOURNAL OF CLINICAL ONCOLOGY

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer

(2017) Veronica Tisato et al.   Journal of Hematology & Oncology

MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer

(2017) Matthias Choschzick et al.   Cancer Biomarkers

A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)

(2016) Farhad Ravandi et al.   LEUKEMIA RESEARCH

Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study

(2016) Rishi R. Lulla et al.   NEURO-ONCOLOGY

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

(2016) Joonil Jung et al.   Nature Communications

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

(2015) M. Andreeff et al.   CLINICAL CANCER RESEARCH

The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents

(2015) J. Canon et al.   MOLECULAR CANCER THERAPEUTICS

Regulation of p53: a collaboration between Mdm2 and Mdmx

(2015) Dongsheng Pei et al.   Oncotarget

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

(2014) Daqing Sun et al.   JOURNAL OF MEDICINAL CHEMISTRY

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours

(2013) M A Warso et al.   BRITISH JOURNAL OF CANCER

Subcellular localization of Mdm2 expression and prognosis of breast cancer

(2013) Hyung Seok Park et al.   International Journal of Clinical Oncology

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

(2012) Isabelle Ray-Coquard et al.   LANCET ONCOLOGY

Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation

(2010) S. D. Konduri et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A survey of glioblastoma genomic amplifications and deletions

(2009) Shailaja K. Rao et al.   JOURNAL OF NEURO-ONCOLOGY

Well-differentiated and dedifferentiated liposarcomas

(2009) Jean-Michel Coindre et al.   VIRCHOWS ARCHIV

Single-nucleotide Polymorphisms in the p53 Signaling Pathway

(2009) L. F. Grochola et al.   Cold Spring Harbor Perspectives in Biology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER